AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
+3.46%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$368M
AUM Growth
+$368M
(+24%)
Cap. Flow
+$61.2M
Cap. Flow
% of AUM
16.61%
Top 10 Holdings %
Top 10 Hldgs %
80.73%
Holding
256
New
50
Increased
100
Reduced
30
Closed
47
Top Buys
| 1 |
iShares MBS ETF
MBB
|
$24.9M |
| 2 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
$22.9M |
| 3 |
Rithm Capital
RITM
|
$2.6M |
| 4 |
Ouster
OUST
|
$1.06M |
| 5 |
Travere Therapeutics
TVTX
|
$897K |
Top Sells
| 1 |
RAVN
Raven Industries Inc
RAVN
|
$1.53M |
| 2 |
Luminar Technologies
LAZR
|
$1.22M |
| 3 |
uniQure
QURE
|
$1.1M |
| 4 |
NUAN
Nuance Communications, Inc.
NUAN
|
$1.09M |
| 5 |
AgEagle Aerial Systems
UAVS
|
$783K |
Sector Composition
| 1 | Real Estate | 18.83% |
| 2 | Healthcare | 12.69% |
| 3 | Technology | 1.7% |
| 4 | Industrials | 0.97% |
| 5 | Financials | 0.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cogent Biosciences
COGT
$1.83B
| $993K | 0.27% |
122,500
+32,500
| +36% | +$263K |
|
27
ClearPoint Neuro
CLPT
$291M
| $955K | 0.26% |
50,000
| – | – |
|
28
Merck
MRK
$210B
| $933K | 0.25% |
12,000
-3,196
| -21% | -$248K |
|
|
29
Travere Therapeutics
TVTX
$1.75B
| $897K | 0.24% |
+61,500
| New | +$897K |
|
|
MOR
30
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $876K | 0.24% |
45,500
+26,500
| +139% | +$510K |
|
31
Iovance Biotherapeutics
IOVA
$800M
| $872K | 0.24% |
33,500
+30,500
| +1,017% | +$794K |
|
|
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
| $864K | 0.23% |
50,000
+23,000
| +85% | +$397K |
|
33
Karyopharm Therapeutics
KPTI
$61.4M
| $841K | 0.23% |
5,433
+1,966
| +57% | +$304K |
|
34
Celldex Therapeutics
CLDX
$1.57B
| $836K | 0.23% |
25,000
| – | – |
|
35
Gilead Sciences
GILD
$140B
| $813K | 0.22% |
11,800
| – | – |
|
36
Axsome Therapeutics
AXSM
$6.09B
| $810K | 0.22% |
12,000
+2,000
| +20% | +$135K |
|
37
Microbot Medical
MBOT
$172M
| $794K | 0.22% |
100,000
| – | – |
|
38
Gyre Therapeutics
GYRE
$734M
| $790K | 0.21% |
24,333
+16,333
| +204% | +$530K |
|
|
ICAD
39
DELISTED
iCAD Inc
ICAD
| $779K | 0.21% |
+45,000
| New | +$779K |
|
40
BioXcel Therapeutics
BTAI
$52.7M
| $727K | 0.2% |
1,563
| – | – |
|
41
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $712K | 0.19% |
51,500
+40,500
| +368% | +$560K |
|
42
Insmed
INSM
$30.3B
| $683K | 0.19% |
24,000
+22,900
| +2,082% | +$652K |
|
|
TCRR
43
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $673K | 0.18% |
41,000
+35,500
| +645% | +$583K |
|
|
MFA
44
MFA Financial
MFA
$1.05B
| $671K | 0.18% |
+36,540
| New | +$671K |
|
45
BioMarin Pharmaceuticals
BMRN
$11.3B
| $668K | 0.18% |
8,000
| – | – |
|
|
ONIT
46
Onity Group Inc.
ONIT
$339M
| $665K | 0.18% |
+21,477
| New | +$665K |
|
47
Aclaris Therapeutics
ACRS
$223M
| $650K | 0.18% |
+37,000
| New | +$650K |
|
48
Spyre Therapeutics
SYRE
$1.02B
| $644K | 0.17% |
3,700
+2,860
| +340% | +$498K |
|
49
ADC Therapeutics
ADCT
$370M
| $633K | 0.17% |
26,000
+9,000
| +53% | +$219K |
|
50
Mr. Cooper
COOP
$12.1B
| $633K | 0.17% |
+19,139
| New | +$633K |
|